1st RNA-based test for targeted treatment eligibility. expressPIK makes the right choice of treatment a reality.


Our Product

As pioneers in the field, we proudly offer the first RNA-based test for targeted treatment eligibility. By harnessing the power of RNA analysis, we provide a comprehensive understanding of a patient's tumour genetic profile, enabling healthcare providers make informed decisions about tailored treatment options.

Fast and Accurate

RNA tests are fast and have unwavering accuracy.


Affordable price for hospitals and clinical labs.

Treatment Aid Resource

Harnessing the power of RNA-based testing to guide personalized treatment decisions.

0 +

Breast Cancer deaths in 2020

0 %

False positive indication

0 K €

for every patient unnecessarily treated

0 +

Awards Won

Patients are being misguided for Treatment.

expressTEC, the 1st RNA-based test, will contribute to advancements in precision medicine positively impacting the lives of breast cancer patients worldwide.

How We Work

Accurate, Easy and Fast to implement.

Our mission is to empower healthcare professionals with fast and reliable tools that identify the most suitable patients for treatment, ensuring optimal therapeutic efficacy while minimising side effects.

Our Product

Winner of the 'Altice International Innovation Award 2023'

This technology allows "signing the personalisation of a therapy". The recognition, in turn, represents an "opportunity to learn to develop the business side and the transfer of technology, something that scientists are little used to".


RNA in-vitro companion diagnostic test for PIQRAY® treatment eligibility
  • Testing tumour RNA
  • Targetable mutations
  • Reliable tool
  • Minimising side effects
  • Increase response to treatment
  • Improve the assessment of the risk of disease

Available Soon.

expressPIK 2n Generation
  • able to advise on dosage adjustment on a patient-by-patient basis

Available Soon.

  • Available Soon

We have 30+ years of experience in Cancer Research.

Both co-founders are experienced researchers in human and cancer genetics, particularly in
breast cancer genomics. Both have a successful past in securing research funding and leading


Our Team

Our team boasts a remarkable blend of diverse talents, seamlessly integrating scientific expertise with business acumen. We foster a dynamic, multidimensional approach that fuels innovation and drives transformative results.


About expressTEC

The project has garnered recognition and validation from experts. These endorsements highlight the project's quality and positive impact on the professional community, solidifying its credibility and success.

Support us

Support us and start to promote this idea.

We want to contribute to impacting the lives of breast cancer patients worldwide.


Latest News

Stay up to date with the main news about the project expressTEC

Get In Touch

If you're keen to collaborate with us...

expressTEC is currently looking for partner institutions (Hospitals and Clinical labs) to conduct Clinical Trials for the products in its pipeline. Please contact us if your institution wants to know more about this opportunity.